Relapses are more frequent among porphyria cutanea tarda patients who had previously achieved remission with antimalarial medications, a study shows. The study, “Relapse of porphyria cutanea tarda after treatment with phlebotomy or 4‐aminoquinoline antimalarial: A Meta‐analysis,” was published in the British Journal of Dermatology.
News
The National Organization for Rare Disorders (NORD) will celebrate the 35th anniversary of both the 1983 Orphan Drug Act and NORD’s founding at a dinner tonight in Washington, D.C. The 2018 Rare Impact Awards, to be held at the Andrew W. Mellon Auditorium, will be webcast via Facebook for those…
The European Union isn’t doing enough to protect the 30 million or so people with rare diseases who live in its 28 member countries, officials meeting last week in Vienna said. More than 900 people from 58 nations attended the 9th European Conference on Rare Diseases & Orphan Drugs (ECRD),…
Acute intermittent porphyria (AIP) patients who have recurrent attacks are more likely to be sicker and unemployed, yet face higher medical costs than patients with occasional attacks, researchers in The Netherlands report. Their study, “Medical and financial burden of acute intermittent porphyria,” was published in the Journal of…
News
FDA Grants Orphan Drug Status to AMP-L2.7.D7 for Treatment of Congenital Erythropoietic Porphyria
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to AMP-L2.7.D7 (ciclopirox) for treatment of Congenital Erythropoietic Porphyria (also known as Gunther’s disease). AMP-L2.7.D7, developed by Atlas Molecular Pharma, is a pharmacological chaperone — a molecule that binds to uroporphyrinogen III synthase, the…
Investigative drug candidate givosiran significantly reduced porphyria attacks in two clinical trials, according to a recent presentation at the European Association for the Study of the Liver (EASL) 53rdAnnual International Liver Congress, in Paris, France. The presentation on the safety and efficacy data of givosiran in patients…
Credit: APF April 21-28, 2018 is Porphyria Awareness Week, and the American Porphyria Foundation (APF) is encouraging everyone to join them in raising awareness and spreading information about porphyria. Porphyria is the term used to refer to a…
A little-known government entity within the National Institutes of Health (NIH) is helping to lead U.S. efforts to speed up the development of therapies for some 7,000 rare diseases. The Office of Rare Diseases Research (ORDR), headquartered in Bethesda, Maryland, was established in 1993 within the NIH Office of the…
The diagnosis of porphyria often is delayed, which highlights the need for increased awareness among clinical physicians. A case report by researchers in the United Kingdom illustrates that point as it describes a patient with acute intermittent porphyria that, despite having all the classical clinical features, was diagnosed tardily. The…
Mitochondrial disorders are complex conditions for which few treatments are available. Now, using microscopic worms, researchers at The Children’s Hospital of Philadelphia (CHOP), are researching if existing human drugs aimed at improving metabolism and restore shortened lifespans, can open the opportunity for human clinical trials on innovative therapies for these…
Recent Posts
- Liver transplant was ‘Trojan horse’ for baby’s variegate porphyria
- With AIP, even minor decisions can have a big impact on life
- Study explains mystery of metabolite rise in ALAD porphyria
- Basic urine test helps doctors in Sri Lanka diagnose rare porphyria
- Blood stem cell transplant corrects defect underlying EPP in 16-year-old
- Woman’s long journey to diagnosis highlights inequalities in AIP care
- Disappointed by the FDA’s ruling on an investigational EPP treatment
- The importance of being able to explain our porphyria symptoms
- Unexplained abdominal pain and low sodium reveal AHP diagnosis